Clinical stage partners Ariceum Therapeutics is a private, clinical-stage radiopharmaceutical company focusing on diagnosis and precision treatment of aggressive cancers, presenting opportunities for collaboration or licensing in late-stage development or companion diagnostics to accelerate clinical programs.

Key asset leverage Lead candidate SSO110 labeled with 177Lu and 255Ac targets SSTR2 in neuroendocrine tumors, offering potential co-development or supply partnerships for theranostic radiopharmaceuticals and expansions into small cell lung cancer and Merkel cell carcinoma indications.

Radiopharma partnerships Recent activity includes acquisitions and supply agreements (Theragnostics Ltd, ITM collaboration for Ac-225 supply, NorthStar partnership), signaling openness to external manufacturing, distribution, and radiolabel supply arrangements that can be tapped for scale.

Financial and investor interest With funding around $25M and strategic investors, there is appetite for collaborations that de-risk manufacturing, clinical development, or regional registrations, including potential co-investment or milestone-based deals aligned with Phase 1/2 milestones.

Global footprint Operations across Germany, Switzerland, Australia, the UK, and the US, plus Ipsen's prior involvement and a Berlin headquarters, provide access to multi-regional regulatory pathways and market access teams for cross-border trials, supply, and commercialization opportunities.